Table 4.
Sensitivity analyses: using models type 2 specification, optimistic and pessimistic scenarios, complete case analyses*
| NHS + PSS perspective | Societal perspective | |
|---|---|---|
| Models type 2 | ||
| ICER (£/QALY) | £5,819 | £6,299 |
| Prob. cost‐effectiveness, % | 95.22 | 94.14 |
| INMB (95% CI) | £769 (£291, £1,247) | £745 (£308, £1,183) |
| Optimistic scenario | ||
| ICER (£/QALY) | £4,914 | £6,086 |
| Prob. cost‐effectiveness, % | 94.42 | 92.62 |
| INMB (95% CI) | £763 (£237, £1,289) | £708 (£225, £1,191) |
| Pessimistic scenario | ||
| ICER (£/QALY) | £12,960 | £14,084 |
| Prob. cost‐effectiveness, % | 77.11 | 73.10 |
| INMB (95% CI) | £365 (–£169, £882) | £301 (–£181, £783) |
| Complete case | ||
| ICER (£/QALY) | £9,282 | £9,410 |
| Prob. cost‐effectiveness, % | 76.01 | 75.95 |
| INMB (95% CI) | £419 (–£195, £1,034) | £428 (–£149, £1,007) |
*
Incremental net monetary benefit statistics (INMB) (95% confidence intervals [95% CIs]) were measured at a willingness‐to‐pay threshold of £20,000 per quality‐adjusted life year (QALY). ICER = incremental cost‐effectiveness ratio; NHS + PSS = National Health System + Personal Social Services; prob. = probability.